-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Irritable bowel syndrome (IBS) is a gastrointestinal functional disorder characterized by chronic or recurrent abdominal pain and changes in bowel habits.
systematic review showed that probiotics were effective in improving IBS symptoms, but the heterogeneity between studies was significant, hindering the development of optimal probiotic strategies for IBS patients.
, more good randomized controlled trials are needed.
recently, a randomized, double-blind, placebo-controlled, multi-center study published in Nutrinents showed that L. acidophilus DDS-1 and B. lactic acid bacteria UABla-12 improved IBS symptoms in IBS adults.
study investigated the clinical efficacy of two probiotic strains on the severity and symptoms of abdominal pain in irritable bowel syndrome (IBS).
according to the Roman IV standard, 330 IBS adults aged 18-70 were randomly assigned (1:1:1) to receive a placebo, Lactobacillus acidophilus DDS-1 (1×1010 CFU/day) or animal Bifidobacteria subsethic Lactobacillus UABla-12 (1×1010 CFU/day) for six weeks.
result of this is a change in abdominal pain severity-numerical score sheet (APS-NRS).
results showed that both groups of probiotics significantly improved the absolute value of APS-NRS (DDS-1:-2.59±2.07, p-0.001; UABla-12:-1.5) during the intervention. 6±1.83, p s 0.001) and percentage of significant responders (DDS-1:52.3%, p slt;0.001);
DDS-1 (-133.4±95.19, p<0.001) and Lactobacillus Lactobacillus UABla-12 (-104.5) ± IBS-SSS scores in the IBS-SSS group of 96.08, p<0.001) were significantly improved compared to placebos, including sub-scores associated with abdominal pain, bloating, detox habits, and quality of life.
, the stool viscosity of both groups of probiotic patients was significantly normalized over time compared to placebo.
, the results showed that L. acidophilus DDS-1 and B. lactic acid bacteria UABla-12 improved the abdominal pain and symptom severity scores of IBS adults and normalized the detox habits of patients accordingly.
